Over 80 genetic markers that can increase the risk of developing breast, prostate or ovarian cancer have been found in the largest study of its kind, which involved 200,000 people. The DNA of the test subjects, half of whom had cancer while the other half did not, was compared to reveal an individual's inherited risk of the diseases. British scientists, who led the research, believe it could lead to a DNA screening test within five years.
The research was led by scientists at the University of Cambridge, and the Institute of Cancer Research (ICR) in London and funded by Cancer Research UK (CRUK) and the Welcome Trust. The main findings of the research are published in five articles in the journal Nature Genetics.
Study author Professor Doug Easton said: "We're on the verge of being able to use our knowledge of these genetic variations to develop a test that could complement breast cancer screening and take us a step closer to having an effective prostate cancer screening programme."
The scientists were looking for common genetic variations - known as single nucleotide polymorphisms (Snps) - linked to the three cancers. Each alteration they found increased the patient's risk of cancer by a small amount, but a small minority of men with lots of the markers could see their risk of prostate cancer increase more than fourfold, and for women the breast cancer risk increased threefold.
The test could also help the one in 300 women who carry a faulty gene known as BRCA1 or BRCA2. Two thirds of them will develop breast cancer before the age of 80 and 45% who carry BRCA1 will get ovarian cancer. By combining the gene test for BRCA1 and BRCA2 with this extra genetic information, women who have a high number of the newly identified markers could find they have nearly a 100% risk of getting breast cancer. In contrast, those with the protective versions of the genetic changes could see their risk drop to as little as 20%.
Dr Antonis Antoniou, CRUK senior fellow at the University of Cambridge, said: "Our research puts us on the verge of being able to give women a much more accurate picture of how likely they are to develop breast or ovarian cancer and would help to guide them about the most appropriate type and time of prevention or monitoring options for them."
The research also sheds light on the risk of prostate cancer in men, which unlike breast cancer does not currently have a screening programme. The average lifetime risk of a man developing prostate cancer is one in eight, but for the 1% who carry a significant number of genetic alterations, the risk rises to one in two. Sixteen of the 23 newly identified genetic markers are associated with aggressive forms of the disease so may help clinicians and patients decide on the best form of treatment. Prof Ros Eles, from the ICR, said: "These results are the single biggest leap forward in finding the genetic causes of prostate cancer." He went on to say: "If further studies show such men benefit from regular screening, we could have a big impact on the number of people dying from the disease, which is still far too high."
Jack
No comments:
Post a Comment